跳至主要内容
临床试验/NCT04797143
NCT04797143招募中不适用

Impact of a Multidisciplinary Consultation Program on Drug Adherence in First Oral Anticancer Treatment

Centre Hospitalier Universitaire, Amiens1 个研究点 分布在 1 个国家目标入组 300 人开始时间: 2021年3月11日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
300
试验地点
1
主要终点
medication possession ratio (MPR)

研究概览

简要总结

Oncology management has changed dramatically over the last decade with the approval and rapid adoption of newly targeted oral oncology medications. The movement to oral oncology medications has altered the balance of risks and adverse effects (AEs) in the treatment of cancer care. These treatments are associated with a different constellation of AEs and drug interactions. Patients receiving treatment with oral anticancer treatment (OAT) encounter several barriers to adherence, which may include limited access to specialty medications, severe adverse effects, complex medication regimens, and special handling precautions. Medication nonadherence not only reduces the efficacy of drug therapy but also has the potential to increase healthcare expenditures due to disease-related hospitalizations. The purpose of this study is to evaluate the drug adherence in cancer patients, using the medication possession ratio (MPR), before and after the implementation of a multidisciplinary consultation program (MCP), on initiation of OAT.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • French speaking patients with a newly diagnosed or relapsed cancer, regardless of location and introduction of oral anticancer treatment

排除标准

  • patients treated with hormone therapy only
  • Patient with severe psychiatric disorders
  • patient who does not speak the French language

结局指标

主要结局

medication possession ratio (MPR)

时间窗: one year

The MPR makes it possible to determine the percentage of days of treatment covered by pharmacy dispensing. A patient is generally considered observant if MPR is greater than or equal to 80%.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验